Cargando…

Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway

Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Achkar, Iman W., Abdulrahman, Nabeel, Al-Sulaiti, Hend, Joseph, Jensa Mariam, Uddin, Shahab, Mraiche, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896132/
https://www.ncbi.nlm.nih.gov/pubmed/29642900
http://dx.doi.org/10.1186/s12967-018-1471-1
_version_ 1783313782694477824
author Achkar, Iman W.
Abdulrahman, Nabeel
Al-Sulaiti, Hend
Joseph, Jensa Mariam
Uddin, Shahab
Mraiche, Fatima
author_facet Achkar, Iman W.
Abdulrahman, Nabeel
Al-Sulaiti, Hend
Joseph, Jensa Mariam
Uddin, Shahab
Mraiche, Fatima
author_sort Achkar, Iman W.
collection PubMed
description Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin.
format Online
Article
Text
id pubmed-5896132
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58961322018-04-20 Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway Achkar, Iman W. Abdulrahman, Nabeel Al-Sulaiti, Hend Joseph, Jensa Mariam Uddin, Shahab Mraiche, Fatima J Transl Med Review Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin. BioMed Central 2018-04-11 /pmc/articles/PMC5896132/ /pubmed/29642900 http://dx.doi.org/10.1186/s12967-018-1471-1 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Achkar, Iman W.
Abdulrahman, Nabeel
Al-Sulaiti, Hend
Joseph, Jensa Mariam
Uddin, Shahab
Mraiche, Fatima
Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
title Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
title_full Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
title_fullStr Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
title_full_unstemmed Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
title_short Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
title_sort cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896132/
https://www.ncbi.nlm.nih.gov/pubmed/29642900
http://dx.doi.org/10.1186/s12967-018-1471-1
work_keys_str_mv AT achkarimanw cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway
AT abdulrahmannabeel cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway
AT alsulaitihend cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway
AT josephjensamariam cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway
AT uddinshahab cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway
AT mraichefatima cisplatinbasedtherapytheroleofthemitogenactivatedproteinkinasesignalingpathway